Incyte and Genmab launch Phase 1/2 trial of KRAS G12D inhibitor and bispecific antibody in metastatic colorectal cancer
+2 new sources since this summary was written
Incyte and Genmab announced a joint Phase 1/2 study that will test Incyte's oral KRAS G12D inhibitor INCB161734 together with Genmab's bispecific antibody petosemtamab and standard chemotherapy. The trial targets patients with KRAS G12D‑mutated metastatic colorectal cancer in the first‑line setting. Incyte will co‑fund the study and provide the supply of INCB161734, while Genmab will lead the clinical execution.
Why it matters
The collaboration adds a KRAS‑targeted candidate to Incyte's oncology pipeline and gives Genmab a new indication for its bispecific platform, which could generate future revenue if the trial shows positive results. Investors should note that Incyte will incur co‑funding costs and Genmab will assume trial management responsibilities.
Key facts
- 1Incyte and Genmab will conduct a Phase 1/2 trial of INCB161734 plus petosemtamab and chemotherapy. stocktitan.net
- 2The study focuses on KRAS G12D‑mutated metastatic colorectal cancer in the first‑line setting. stocktitan.net
- 3Incyte will co‑fund the trial and supply the investigational KRAS inhibitor INCB161734. stocktitan.net
- 4Genmab will lead the clinical conduct of the Phase 1/2 study. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.